Gelonghui, August 4?Some investors asked Shuanglu Pharmaceutical (002038.SZ), "how is the progress of the company's research and development of Lilaluptide, and when is it expected to be listed?"
Shuanglu Pharmaceutical replied that Lilarutide is in the third stage of data collation, and it is difficult to estimate the production time.